Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Background Antiresorptive agents such as bisphosphonates and denosumab, as well as
angiogenesis inhibitors, may induce medication-related osteonecrosis of the jaw (MRONJ) …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

It is well established that alterations in phosphate metabolism have a profound effect on
hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the …

Bone is in a constant state of remodeling, a process which was once attributed solely to
osteoblasts and osteoclasts. Decades of research has identified many other populations of …

Osteonecrosis of the jaw (ONJ) was defined as exposed, necrotic bone in the maxillofacial
region for at least 8 weeks in patients receiving an antiresorptive medication for primary or …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Medication-related osteonecrosis of the jaw is an oral complication in cancer patients being
treated with either antiresorptive or antiangiogenic drugs. The first reports of MRONJ were …

The aim was to investigate the effect of groove designs on bone quality under controlled-
repetitive load conditions for optimizing dental implant design. Anodized Ti-6Al-4V alloy …

Over a century after the first synthesis of bisphosphonates (1897) and a decade (2003) since
the initial report on bisphosphonate-related osteonecrosis of the jaw (ONJ), this osteopathy …